Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21654386)

  • 1. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma in relapse: the role of emerging new drugs.
    Diefenbach CS; O'Connor OA
    Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction inhibitors in chronic lymphocytic leukemia.
    Ma S; Rosen ST
    Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
    Delmonte A; Ghielmini M; Sessa C
    Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
    Jahangiri S; Friedberg J; Barr P
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
    Rodgers TD; Reagan PM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for B-cell non-Hodgkin lymphoma.
    Briones J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs and targeted treatments in Hodgkin's lymphoma.
    Provencio M; Sánchez A; Sánchez-Beato M
    Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors in lymphoma.
    Copeland A; Buglio D; Younes A
    Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell receptor pathobiology and targeting in NHL.
    Macias-Perez IM; Flinn IW
    Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
    Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
    Moskowitz CH
    J Nucl Med; 1998 Aug; 39(8 Suppl):2S-10S. PubMed ID: 9708564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Mukherji D; Pettengell R
    Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.